CollPlant Biotechnologies (CLGN) Interest Expenses (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Interest Expenses came in at $28.8 million in Q4 2025, up 3796.35% YoY from $740000.0 in Q4 2024, and up 3796.35% on a QoQ basis from $740000.0 in Q4 2024.
CollPlant Biotechnologies (CLGN) Interest Expenses (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Interest Expenses data on file, last reported at $28.8 million in Q4 2025.
- Quarterly Interest Expenses rose 3796.35% year-over-year to $28.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $28.8 million (up 3625.19% YoY) and the FY2025 annual result came in at $28.8 million, up 26.64% from the prior year.
- Interest Expenses advanced to $28.8 million in Q4 2025, from $740000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $35.7 million in Q4 2021 to a low of -$8.0 million in Q3 2021.
- A 5-year average of $5.8 million and a median of $149000.0 in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2021 — Interest Expenses slumped 500.0% — and 2025, when it surged 3796.35%.
- Tracing CLGN's Interest Expenses over 5 years: stood at $35.7 million in 2021, then sank by 37.07% to $22.5 million in 2022, then sank by 100.2% to -$45000.0 in 2023, then jumped by 1744.44% to $740000.0 in 2024, then surged by 3796.35% to $28.8 million in 2025.
- The last three Interest Expenses figures came in at $28.8 million (Q4 2025), $740000.0 (Q4 2024), and -$46000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28.83 Mn |
| Dec 31, 2025 | 28.83 Mn |
| Dec 31, 2024 | 740,000.00 |
| Dec 31, 2024 | 740,000.00 |
| Sep 30, 2024 | -46,000.00 |
| Sep 30, 2024 | -46,000.00 |
| Jun 30, 2024 | 335,000.00 |
| Jun 30, 2024 | 335,000.00 |
| Mar 31, 2024 | 125,000.00 |
| Mar 31, 2024 | 125,000.00 |
| Dec 31, 2023 | -45,000.00 |
| Dec 31, 2023 | -45,000.00 |
| Sep 30, 2023 | 113,000.00 |
| Sep 30, 2023 | 113,000.00 |
| Jun 30, 2023 | 173,000.00 |
| Jun 30, 2023 | 173,000.00 |
| Mar 31, 2023 | 282,000.00 |
| Mar 31, 2023 | 282,000.00 |
| Dec 31, 2022 | 22.47 Mn |
| Dec 31, 2022 | 22.47 Mn |